DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,629,875 B2 Lentini Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,629,875 B2 Lentini Et Al US009629875B2 (12) United States Patent (10) Patent No.: US 9,629,875 B2 Lentini et al. (45) Date of Patent: Apr. 25, 2017 (54) CLOSTRIDIUM DIFFICILE SPORCIDAL (58) Field of Classification Search COMPOSITIONS None See application file for complete search history. (71) Applicant: Microdermis Corporation, Princeton, NJ (US) (56) References Cited (72) Inventors: Peter J. Lentini, Tarrytown, NY (US); U.S. PATENT DOCUMENTS Dawn Lembo, Leonia, NJ (US) 4,271,149 A 6, 1981 Winicov et al. 5,665,307 A 9, 1997 Kirschner et al. (73) Assignee: Microdermis Corporation, Princeton, 5,885,620 A 3, 1999 Foret NJ (US) 2009/0324737 A1* 12/2009 Walker ................... A61K 8,347 424,616 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 0 days. WO WO-00,054594 A1 9, 2000 (21) Appl. No.: 14/683,276 OTHER PUBLICATIONS Filed: Apr. 10, 2015 (22) Kelemen WO 2000/054594 A1, Sep. 2000.* Prior Publication Data Gershenfeld, L. and Witlin, B., Iodine as an antiseptic, Ann. NY (65) Acad. Sci., 53(1): 172-82 (1950). US 2016/0058,789 A1 Mar. 3, 2016 International Search Report for PCT/US2015/025259, 3 pages (Jun. 26, 2015). Related U.S. Application Data Written Opinion for PCT/US2015/025259, 8 pages (Jun. 26, 2015). (60) Provisional application No. 61/978,451, filed on Apr. * cited by examiner 11, 2014. Primary Examiner — Robert A Wax (51) Int. Cl. Assistant Examiner — Quanglong Truong A6 IK3I/74 (2006.01) (74) Attorney, Agent, or Firm — Choate, Hall & Stewart A6 IK 33/18 (2006.01) LLP: Brenda Herschbach Jarrell A6 IK3I/I94 (2006.01) AOIN 37/36 (2006.01) (57) ABSTRACT AOIN 59/2 (2006.01) Disclosed are sporicidal compositions, and methods of use AOIN 43/36 (2006.01) thereof. The sporicidal compositions contain water, an A6 IK 9/00 (2006.01) organic Solvent, and a spore-germinating agent containing A 6LX 3L/79 (2006.01) an iodide source, a citrate source or both. The compositions (52) U.S. C. have sporicidal activity against, e.g., Clostridium difficile CPC .............. A61K 33/18 (2013.01); A0IN 37/36 spores. The sporicidal compositions can be used alone, or (2013.01); A0IN 43/36 (2013.01); A0IN can form part of a disinfecting composition or an antiseptic 59/12 (2013.01); A61K 9/0014 (2013.01); composition. A61K 31/194 (2013.01); A61 K3I/79 (2013.01) 17 Claims, 2 Drawing Sheets U.S. Patent Apr. 25, 2017 Sheet 1 of 2 US 9,629,875 B2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - C. difficile Spore Count after Contact 8 CFU/mL (x10^5) FG, U.S. Patent Apr. 25, 2017 Sheet 2 of 2 US 9,629,875 B2 1000000 g--------------------------------------------------------------- 100000 - : : x contro 8& control 10000 :- ; : & FF-B. & FF-B. 1000 --~ w8w, FF.B.2 w8.FF.B.2 O -------------------- 10 gr:rixx-x-xx-r FF-G2 ... FF-G2 1 -: initia 2 s O F.G. 2 US 9,629,875 B2 1. 2 CLOSTRIDIUM DIFFICILE SPORCIDAL FIG. 2 shows reduction in C. difficile spore count after COMPOSITIONS contact with provided compositions according to Example 32. BACKGROUND DETAILED DESCRIPTION OF CERTAIN Spore-forming Clostridium difficile-associated diseases EMBODIMENTS (CDAD) remain an important nosocomial infection associ ated with significant morbidity and mortality. In recent years, the incidence of CDAD has unfortunately increased Definitions and Usage and high rates of recurrent disease continue with currently Unless otherwise specified, the word “includes” (or any available treatment regimens. Typically, Clostridium difficile 10 variation thereon, e.g., “include”, “including, etc.) is is transmitted by the fecal-oral route. Spores that persist in intended to be open-ended. For example, “A includes 1, 2 the environment Survive the gastric acid barrier and germi and 3’ means that A includes but is not limited to 1, 2 and nate in the colon. Toxins released from vegetative C. difficile 3. cells are responsible for clinical CDAD. Unless otherwise specified, the word “about’, when used Vegetative C. difficile can only survive 15 minutes aero- 15 to modify a numeric quantity, meanst8% of the numeric bically, but the bacteria are nonetheless very difficult to value. Thus, “about 5” means 4.6-5.4, “about 70” means eradicate because they form spores. C. difficile spores can be 64-76, etc. For this purpose, percentage values are consid found as airborne particles, attached to inanimate Surfaces ered as their nominal quantities, e.g., 5% is treated as 5 Such as hard Surfaces and fabrics, and attached to Surfaces of rather than 0.05. Thus, “about 5% means 4.6%-5.4%, living organisims, such as skin and hair. Spores can be found 20 “about 70% means 64%-76%, etc. on a patient’s skin as well as on any surface in the room that As used herein, the term "sporicidal' has the meaning the infected patient occupied. During exams these spores ascribed to it in the section labeled “Sporicidal Composi can be transferred to the hands and body of healthcare tions', below. workers and thereby spread to Subsequent equipment and Clostridium difficile Spores areas they contact. 25 Clostridium difficile, also known as "CDF/cdf or “C. Hospital discharges for CDAD in the United States diff", a species of Gram-positive, spore-forming anaerobic doubled between 1996 and 2003. These nosocomial infec tions are extremely costly to hospitals at S1.28 to S9.55 bacillus, can lead to severe complications ranging from billion annually in the U.S. alone, mostly due to infected antibiotic-associated diarrhea (AAD) to severe life-threat patients requiring extended stays of 3.6 to 14.4 days. Com ening pseudomembranous colitis, a severe infection of the plications of CDAD include life-threatening diarrhea, 30 colon. In fact, C. difficile is the cause of approximately 25% pseudo-membranous colitis, toxic megacolon, sepsis, and of all cases of antibiotic-associated diarrhea. Most cases of death. Expenses related to treatment of these conditions C. difficile-associated disease (CDAD) occur in hospitals or ranges from S3,669 to S27,290 per patient. CDAD causes long-term care facilities causing more than 300,000 cases death in 1-2% of affected patients. per year in the United States alone. The total US hospital People are most often infected in hospitals, nursing 35 costs for CDAD management have been estimated to be $3.2 homes, or institutions, although C. difficile infection in the billion per year. community, outpatient setting is increasing. C. difficile Clostridia are motile bacteria that are ubiquitous in nature infection (CDI) can range in severity from asymptomatic to and are especially prevalent in soil. Under microscopy, severe and life-threatening, especially among the elderly. clostridia appear as long drumstick-like irregularly-shaped The rate of C. difficile acquisition is estimated to be 13% in 40 cells with a bulge at their terminal ends. Clostridium difficile patients with hospital stays of up to 2 weeks, and 50% in cells show optimum growth on blood agar at human body those with hospital stays longer than 4 weeks. temperatures in the absence of oxygen. When stressed, the While currently available antibiotics used for treatment of bacteria produce spores, which tolerate extreme conditions recurrent CDAD lead to symptomatic improvement, they are that the active bacteria cannot tolerate. essentially ineffective against C. difficile spores, the trans- as In Small numbers, C. difficile do not result in significant missible form of the disease. This causes a high risk of relapse occurring post-therapy as sporulated microorgan disease. The first step in development of C. difficile coloni isms begin to germinate. Therefore, controlling C. difficile zation is the disruption of the normal flora of the colon, infection requires limiting the spread of spores by good usually by antibiotics. Antibotic treatments, especially those hygiene practices, isolation and barrier precautions, and with a broad spectrum of activity, cause disruption, often environmental cleaning. 50 resulting from eradication of the normal intestinal flora by Because of the prevalence of C. difficile in hospitals, antibiotics of normal intestinal flora, leading to an over healthcare workers and researchers have an interest in growth of C. difficile. C. difficile is currently the most developing an agent that can kill C. difficile and its spores. common cause of nosocomial diarrhea with significant mor bidity and mortality. The C. difficile bacteria, which natu SUMMARY 55 rally reside in the human intestines, overpopulate and release toxins that can cause bloating, constipation, or The present invention encompasses the insight that both diarrhea with abdominal pain, which may become severe. citrate and iodide are C. difficile germinants, i.e., they Latent symptoms often mimic Some flu-like symptoms. facilitate germination of C. difficile spores to the vegetative Antibiotic treatment of C. difficile infections can be dif state, where the bacterium is more susceptible to being killed 60 ficult, due both to antibiotic resistance as well as physiologi by stressors, such as antimicrobial agents, heat, and air. cal factors of the bacteria itself. Because the organism forms acid- and heat-resistant spores, C. difficile spores can persist BRIEF DESCRIPTION OF THE DRAWING in the environment for years, and contamination by C. difficile is very common in hospital, clinical, long-term care FIG. 1 shows reduction in C. difficile spore count after 65 or nursing home environments. Often, it can be cultured contact with provided compositions according to Example from almost any surface in a hospital. Patient-to-patient 3.1. transmission of C. difficile spores occurs by sharing medical US 9,629,875 B2 3 4 equipment or facilities in hospitals, nursing homes and other (NH4)2SO4 (40 mg/L), FeSO4.7H2O (4 mg/L), CoCl2.6H2O extended-care facilities.
Load more

Recommended publications
  • Reducing Mg Anode Overpotential Via Ion Conductive Surface Layer Formation by Iodine Additive
    COMMUNICATION Electrolytes www.advenergymat.de Reducing Mg Anode Overpotential via Ion Conductive Surface Layer Formation by Iodine Additive Xiaogang Li, Tao Gao, Fudong Han, Zhaohui Ma, Xiulin Fan, Singyuk Hou, Nico Eidson, Weishan Li,* and Chunsheng Wang* Another challenge is the development Electrolytes that are able to reversibly deposit/strip Mg are crucial for of electrolytes that can effectively utilize rechargeable Mg batteries. The most studied complex electrolytes based an Mg metal anode. Extensive effort has on Lewis acid-base chemistry are expensive, difficult to be synthesized, and been put in to develop electrolytes capable of reversibly depositing/stripping Mg. show limited anodic stability. Conventional electrolytes using simple salts Most work has focused on complex elec- such as Mg(TFSI)2 can be readily synthesized, but Mg deposition/stripping in trolytes that allow fast and reversible Mg these simple salt electrolytes is accompanied by a large overpotential due to deposition/stripping. Such electrolytes the formation of a surface layer on the Mg metal with a low Mg ion conduc- were first proposed by Aurbach’s group [8] tivity. Here the overpotential for Mg deposition/stripping in a simple salt, in 2000, and subsequently they devel- oped the all phenyl complex showing high Mg(TFSI) -1,2-dimethoxyethane (DME), electrolyte is significantly reduced by 2 anodic stability.[9] Later, a non-nucleophilic −3 adding a small concentration of iodine (≤50 × 10 M) as an additive. Mecha- electrolyte, Mg-HMDS, was developed by nism studies demonstrate that an Mg ion conductive solid MgI2 layer is Muldoon and co-workers, and Fichtner formed on the surface of the Mg metal and acts as a solid electrolyte inter- and co-workers for Mg/S batteries.[10,11] To eliminate the organic Grignard species in face.
    [Show full text]
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • Net Ionic Equation Worksheet Answers
    Honors Chemistry Name__________________________________ Period_____ Net Ionic Equation Worksheet READ THIS: When two solutions of ionic compounds are mixed, a solid may form. This type of reaction is called a precipitation reaction, and the solid produced in the reaction is known as the precipitate. You can predict whether a precipitate will form using a list of solubility rules such as those found in the table below. When a combination of ions is described as insoluble, a precipitate forms. There are three types of equations that are commonly written to describe a precipitation reaction. The molecular equation shows each of the substances in the reaction as compounds with physical states written next to the chemical formulas. The complete ionic equation shows each of the aqueous compounds as separate ions. Insoluble substances are not separated and these have the symbol (s) written next to them. Water is also not separated and it has a (l) written next to it. Notice that there are ions that are present on both sides of the reaction arrow –> that is, they do not react. These ions are known as spectator ions and they are eliminated from complete ionic equation by crossing them out. The remaining equation is known as the net ionic equation. For example: The reaction of potassium chloride and lead II nitrate Molecular Equation: 2KCl (aq) + Pb(NO3)2 (aq) -> 2KNO3 (aq) + PbCl2 (s) + - 2+ 3– + – Complete Ionic Equation: 2K (aq) + 2Cl (aq) + Pb (aq) + 2NO (aq) -> 2K (aq) + 2NO3 (aq) + PbCl2 (s) - 2+ Net Ionic Equation: 2Cl (aq) + Pb (aq) -> PbCl2 (s) Directions: Write balanced molecular, ionic, and net ionic equations for each of the following reactions.
    [Show full text]
  • SAFETY DATA SHEET Santa Cruz Biotechnology, Inc
    SAFETY DATA SHEET Santa Cruz Biotechnology, Inc. Revision date 05-Apr-2018 Version 1 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING _____________________________________________________________________________________________________________________ Product identifier Product Name Methyl-d3-magnesium iodide solution Product Code SC-235856 Recommended use of the chemical and restrictions on use For research use only. Not intended for diagnostic or therapeutic use. Details of the supplier of the safety data sheet Emergency telephone number Chemtrec Santa Cruz Biotechnology, Inc. 1.800.424.9300 (Within USA) 10410 Finnell Street +1.703.527.3887 (Outside USA) Dallas, TX 75220 831.457.3800 800.457.3801 [email protected] 2. HAZARDS IDENTIFICATION _____________________________________________________________________________________________________________________ This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200). Classification Acute toxicity - Oral Category 4 Specific target organ toxicity (single exposure) Category 3 Substances or mixtures which, in contact with water, emit Category 1 flammable gases Flammable liquids Label elements Signal word Danger Hazard statements Harmful if swallowed May cause drowsiness or dizziness Extremely flammable liquid and vapor In contact with water releases flammable gases which may ignite spontaneously Symbols/Pictograms Precautionary Statements - Prevention Wash face, hands and any exposed skin thoroughly after handling Do not eat, drink or smoke when using this product Avoid breathing dust/fume/gas/mist/vapors/spray Use only outdoors or in a well-ventilated area Keep away from heat/sparks/open flames/hot surfaces. — No smoking Keep container tightly closed Ground/bond container and receiving equipment Use only non-sparking tools Take precautionary measures against static discharge Wear protective gloves/protective clothing/eye protection/face protection Handle under inert gas.
    [Show full text]
  • IODINE Its Properties and Technical Applications
    IODINE Its Properties and Technical Applications CHILEAN IODINE EDUCATIONAL BUREAU, INC. 120 Broadway, New York 5, New York IODINE Its Properties and Technical Applications ¡¡iiHiüíiüüiütitittüHiiUitítHiiiittiíU CHILEAN IODINE EDUCATIONAL BUREAU, INC. 120 Broadway, New York 5, New York 1951 Copyright, 1951, by Chilean Iodine Educational Bureau, Inc. Printed in U.S.A. Contents Page Foreword v I—Chemistry of Iodine and Its Compounds 1 A Short History of Iodine 1 The Occurrence and Production of Iodine ....... 3 The Properties of Iodine 4 Solid Iodine 4 Liquid Iodine 5 Iodine Vapor and Gas 6 Chemical Properties 6 Inorganic Compounds of Iodine 8 Compounds of Electropositive Iodine 8 Compounds with Other Halogens 8 The Polyhalides 9 Hydrogen Iodide 1,0 Inorganic Iodides 10 Physical Properties 10 Chemical Properties 12 Complex Iodides .13 The Oxides of Iodine . 14 Iodic Acid and the Iodates 15 Periodic Acid and the Periodates 15 Reactions of Iodine and Its Inorganic Compounds With Organic Compounds 17 Iodine . 17 Iodine Halides 18 Hydrogen Iodide 19 Inorganic Iodides 19 Periodic and Iodic Acids 21 The Organic Iodo Compounds 22 Organic Compounds of Polyvalent Iodine 25 The lodoso Compounds 25 The Iodoxy Compounds 26 The Iodyl Compounds 26 The Iodonium Salts 27 Heterocyclic Iodine Compounds 30 Bibliography 31 II—Applications of Iodine and Its Compounds 35 Iodine in Organic Chemistry 35 Iodine and Its Compounds at Catalysts 35 Exchange Catalysis 35 Halogenation 38 Isomerization 38 Dehydration 39 III Page Acylation 41 Carbón Monoxide (and Nitric Oxide) Additions ... 42 Reactions with Oxygen 42 Homogeneous Pyrolysis 43 Iodine as an Inhibitor 44 Other Applications 44 Iodine and Its Compounds as Process Reagents ...
    [Show full text]
  • Chewable Lozenge Formulation
    Umashankar M S et al. Int. Res. J. Pharm. 2016, 7 (4) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 – 8407 Review Article CHEWABLE LOZENGE FORMULATION- A REVIEW Umashankar M S *, Dinesh S R, Rini R, Lakshmi K S, Damodharan N SRM College of Pharmacy, SRM University, Kattankulathur, India *Corresponding Author Email: [email protected] Article Received on: 11/02/16 Revised on: 13/03/16 Approved for publication: 28/03/16 DOI: 10.7897/2230-8407.07432 ABSTRACT Development of lozenges dated back to 20thcentury and is still remain popular among the consumer and hence it has continued commercial production. Lozenges are palatable solid unit dosage form administrated in the oral cavity. They meant to be dissolved in mouth or pharynx for its local or systemic effect. Lozenge tablets provide several advantages as pharmaceutical formulations however with some disadvantages. Lozenge as a dosage form can be adopted for drug delivery across buccal route, labial route, gingival route and sublingual route. Multiple drugs can also be incorporated in them for chronic illness treatments. Lozenge enables loading of wide range of active ingredients for oral systemic delivery of drugs. Lozenges are available as over the counter medications in the form of caramel based soft lozenges, hard candy lozenges and compressed tablet lozenges containing drugs for sore throat, mouth infection and as mouth fresheners. The rationale behind the use of medicated lozenges as one of the most favored dosage form for the delivery of antitussive drugs. This review focuses various aspects of lozenge formulation providing an insight to the formulation scientist on novel application of lozenge drug delivery system.
    [Show full text]
  • Compound Formula Tin (II) Nitride Silver Oxide Lithium Sulfide Magnesium Sulfide
    Ionic Bonding Drill Write the correct formula for the following compounds Compound Formula tin (II) nitride silver oxide lithium sulfide magnesium sulfide copper (I) nitride AgCl boron iodide potassium fluoride copper (I) chloride is CuCl iron (II) oxide is FeO tin (IV) fluoride is SnF4 nickel (II) fluoride is NiF2 lead (IV) oxide is PbO2 silver chloride is calcium iodide is CaI2 potassium bromide sodium phosphide iron (II) chloride copper (I) bromide lead (II) sulfide lead (IV) nitride beryllium nitride potassium bromide is KBr sodium phosphide is Na3P iron (II) chloride is FeCl2 copper (I) bromide is CuBr lead (II) sulfide is PbS lead (IV) nitride is Pb3N4 beryllium nitride is Be3N2 copper (I) chloride iron (II) oxide tin (IV) fluoride nickel (II) fluoride lead (IV) oxide Ag2O silver chloride calcium iodide Answers copper (I) nitride is Cu3N boron iodide is BI3 potassium fluoride is KF silver oxide is lithium sulfide is Li2S magnesium sulfide is MgS tin (II) nitride is Sn3N2 Ionic Bonding Drill Write the correct formula for the following compounds Compound Formula lithium bromide sodium sulfide lead (II) chloride nickel (II) oxide AlBr3 copper (II) oxide AlI3 iron (II) fluoride tin (II) oxide iron (II) oxide is FeO lead (II) oxide is PbO aluminum bromide is potassium oxide is K2O potassium oxide is K2O aluminum iodide is lead (II) nitride is Pb3N2 tin (IV) sulfide iron (III) sulfide lead (II) nitride copper (II) oxide silver fluoride AgF sodium chloride magnesium bromide tin (IV) sulfide is SnS2 iron (III) sulfide is Fe2S3 lead (II)
    [Show full text]
  • Substantial Equivalence Determination Decision Summary Assay Only Template
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k091024 B. Purpose for Submission: Premarket notification C. Measurand: Methicillin Resistant Staphylococcus aureus (MRSA) D. Type of Test: Detection of MRSA using a selective and differential chromogenic media E. Applicant: bioMérieux, Inc. F. Proprietary and Established Names: chromID™ MRSA Agar G. Regulatory Information: 1. Regulation section: 21 CFR 866.1700 2. Classification: Class II 3. Product code: JSO Culture media, Antimicrobial susceptibility test, excluding Mueller Hinton Agar 1 4. Panel: Microbiology H. Intended Use: 1. Intended use(s): chromID™ MRSA agar is a selective and differential chromogenic medium for the qualitative detection of nasal colonization of methicillin resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings. The test is performed on anterior nares swab specimens from patients and healthcare workers to screen for MRSA colonization. chromID™ MRSA agar is not intended to diagnose MRSA infection nor to guide or monitor treatment of infection. 2. Indication(s) for use: The chromID™ MRSA agar is not intended to diagnose MRSA infection nor to guide or monitor treatment of infection. 3. Special conditions for use statement(s): Prescription use 4. Special instrument requirements: Not applicable I. Device Description: The chromID™ MRSA agar is translucent and a light tan color. After the plates are inoculated and incubated, colonies growing on the plates will have either a green appearance, which indicates a positive MRSA status or a colorless appearance which indicates a negative MRSA status. The green color is more vivid if the colonies are observed through the agar from the bottom of the plate.
    [Show full text]
  • Adverse Effects and Precautions
    1736 Disinfectants and Preservatives i Amylmetacresoi (BAN, riNN) ..................Preparat ons........ Adverse Effects and Precautions ProprietaryPreparations (details are given in Volume B) The alkyl gallates may cause contact sensitivity and skin Aml!metacreso!; A[ililrnetakrezol: Amylrnet.acreso[; Amylrne.­ AM<InM<;· Multi-ingredient Preparations. Singapore: Esemdent. reactions. ta�resolurn; Amylmetakresol: Amyylirnetakresoli; TaKpe30J1. Effects on the blood. Methaemoglobinaemia associated 6-Pentyl-rn,cresol; S;Methyl.-2-pentylpheooi. Alkyl Gallates with the antoxidants (butylated hydroxyanisole, butylated C1 J1,80= 178.3 hydroxytoluene, and propyl gallate) used to preserve the CAS 1300,94-3. .de Gaiatos alquilo; AnKwnrannalJ:>t. oil in a soybean infant feed fom1ula has been reported.1 UN!! -'-· 05W904P57F: Propyl gallate was suspected of being the most likely cause Dodecyl Gallate because its chemical structure is similar to pyrogallol Pharmacopoeias. In Bur. (see p. vii). (p. 1718.2), a methaemoglobinaemia inducer. Ph. Eur. 8: (Amylmetacresol). A clear or almost clear liquid Dodecilo galatas; Dociecyle,. gallate Dodecylgallat; . de; ..•. I. Nitzan M, et al. Infantile methemoglobinemia caused by food additives. or a solid crystalline mass, colourless or slightly yellow Dodecyi-9Jilat; D(0ec%lis (iallas:. Dodekyyligallaattl; E312; Clin Toxicol 1979; 15: 273-80. when freshly prepared; it darkens or discolours to dark m Galata • de dodecflo; Laury! Gailate; Laurylum Gafikw ; yellow, brownish-yellow, or pink on keeping. F.p. about 22 }logel\vfn rarinar. Preparations degrees. Practically insoluble in water; very soluble in Dodecyi 3,4,5-trihyc;lroxybenzoate. ...................... alcohol and in acetone. Store in non�metallic airtight (details are given in Volume B) C;ul;lje0$=338.4 ProprietaryPreparations containers. Protect from light.
    [Show full text]
  • Study Protocol
    Study Protocol Proposed methodology to measure the impact of GRIP toolkit materials on antibiotic prescribing for URTIs by primary care physicians The method described here illustrates the process for assessment of one specific symptom of upper respiratory tract infection (URTI), sore throat. This has been selected as the Centor criteria may be used to predict the likelihood of a group A streptococcal bacterial infection in patients complaining of acute sore throat1 while other common URTI symptoms are likely to be due to viral infection. This protocol can be adapted for other URTI symptoms. Using this protocol and analysing the collected data can help understand: • The impact of GRIP toolkit materials on antibiotic prescribing in URTIs • Thether current level of antibiotic use is indicated (e.g. in non-high risk patients) Study arms • Control arm: no access to GRIP toolkit materials (n=tbc) • Test arm: full access to GRIP toolkit materials (n=tbc) Test arm: GRIP URTI toolkit preparation prior to assessment If you are part of the control arm and will not be using the toolkit during this assessment, you do not need to read this section. Please go straight to the patient section below. Preparation and planning • Review current personal and colleague management practices when dealing with URTIs, specifically acute sore throat • Ensure each doctor within the test arm has read and understood the toolkit materials • Identify any differences between current practice versus that advised in the GRIP toolkit Defining use of the GRIP toolkit There are four ways the GRIP toolkit can be used by the test arm.
    [Show full text]
  • 2012 Harmonized Tariff Schedule Pharmaceuticals Appendix
    Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEVALTRATE 25161-41-5 ABAFUNGIN 129639-79-8 ACEXAMIC ACID 57-08-9 ABAGOVOMAB 792921-10-9 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACLIDINIUM BROMIDE 320345-99-1 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURIN 178535-93-8 ACOLBIFENE 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDE 185106-16-5
    [Show full text]
  • Sore Throat in Primary Care Project
    Family Practice, 2015, Vol. 32, No. 3, 263–268 doi:10.1093/fampra/cmv015 Advance Access publication 25 March 2015 Epidemiology Sore throat in primary care project: a clinical score to diagnose viral sore throat Selcuk Mistika,*, Selma Gokahmetoglub, Elcin Balcic, and Fahri A Onukd Downloaded from https://academic.oup.com/fampra/article-abstract/32/3/263/695324 by guest on 31 July 2019 aDepartment of Family Medicine, bDepartment of Microbiology, cDepartment of Public Health, Erciyes University Medical Faculty, Kayseri, Turkey, and dBunyamin Somyurek Family Medicine Centre, Kayseri, Turkey. *Correspondence to Prof. S. Mistik, Department of Family Medicine, Erciyes University Medical Faculty, Kayseri 38039, Turkey; E-mail: [email protected] Abstract Objective. Viral agents cause the majority of sore throats. However, there is not currently a score to diagnose viral sore throat. The aims of this study were (i) to find the rate of bacterial and viral causes, (ii) to show the seasonal variations and (iii) to form a new scoring system to diagnose viral sore throat. Methods. A throat culture for group A beta haemolytic streptococci (GABHS) and a nasopharyngeal swab to detect 16 respiratory viruses were obtained from each patient. Over a period of 52 weeks, a total of 624 throat cultures and polymerase chain reaction analyses were performed. Logistic regression analysis was performed to find the clinical score. Results. Viral infection was found in 277 patients (44.3%), and GABHS infection was found in 116 patients (18.5%). An infectious cause was found in 356 patients (57.1%). Rhinovirus was the most commonly detected infectious agent overall (highest in November, 34.5%), and the highest GABHS rate was in November (32.7%).
    [Show full text]